Cystatin C-based AKI Staging in Critically Ill Patients: Methodological Concerns and Clinical Caveats From a Nephrology Perspective Authors: Meng Li, Zhining Mo Published: 2026 To the Editor: Helmersson-Karlqvist et al.1 propose a cystatin C-based acute kidney injury (AKI) staging system that reclassifies a substantial proportion of critically ill patients and improves long-term mortality prediction. As clinical nephrologists who routinely manage AKI in the intensive care unit, we appreciate the effort to overcome creatinine’s limitations. However, we wish to highlight several clinical and methodological issues that, in our view, limit the immediate applicability of the proposed staging. These issues are as follows- 1. Exclusion of patients with falling biomarkers—a selected cohort The authors excluded all patients with decreasing creatinine or cystatin C from baseline (Supplementary Methods), arguing that the relationship with mortality was uncertain. In clinical practice, a rapid fall in creatinine often reflects fluid resuscitation, withdrawal of nephrotoxins, or early recovery—all of which are prognostically relevant. By excluding these patients, the derivation cohort may have been enriched with a “steady-or-worsening” subset, potentially overestimating the risk associated with cystatin C-based upstaging. The sensitivity of the model to this exclusion criterion is not tested, raising concerns about generalizability to real-world intensive care unit populations with dynamic kidney function trajectories. 2. Glucocorticoid use—a major unmeasured confounder Cystatin C production is increased by corticosteroids, as acknowledged by the authors and supported by multiple studies.2, 3, 4 In the discovery cohort (2006–2013), hydrocortisone for septic shock was standard of care.5 Although the authors performed a post hoc analysis in patients with infections, they did not adjust for actual steroid administration. This is critical because steroid-induced cystatin C elevation could falsely upstage AKI without reflecting true glomerular filtration rate decline. Without drug-level or prescription data, we cannot rule out that part of the “improved sensitivity” of cystatin C is driven by pharmacological artefact rather than renal pathophysiology. 3. Clinical utility—does upstaging change management? The most clinically relevant question—whether cystatin C-based staging guides interventions such as timing of renal replacement therapy or nephroprotective strategies—remains unanswered. The authors demonstrate higher hazard ratios for mortality, but no data on renal replacement therapy initiation, kidney recovery, or progression to chronic kidney disease are provided. In an era of scarce intensive care unit resources, labelling more patients as higher-stage AKI (11% more AKI overall, 10% more stage 3) without evidence that it improves outcomes could lead to unnecessary monitoring, alarm fatigue, or even premature renal replacement therapy. In summary, although the cystatin C-based staging is a scientifically interesting advance, its adoption in clinical practice should await adjustment for steroid use, inclusion of patients with improving kidney function, and demonstration of meaningful changes in patient management. We look forward to further studies that address these nephrology-centric concerns (Figure 1). Proposed mechanism of cystatin C elevation and clinical decision gaps. Glucocorticoids increase cystatin C production independent of glomerular filtration rate, leading to potential AKI upstaging without true renal injury. The lower panel highlights the following missing clinical evidence: renal replacement therapy timing, kidney recovery, and impact on management. AKI, acute kidney injury. Disclosure The authors declare no competing interests. Author Contributions LM and MZ conceptualized the letter, drafted the manuscript, and approved the final version for submission. References